Sitagliptin and Metformin Explained: How Sitomni-M-OD Works

Metformin belongs to the biguanide class, a family with roots in traditional use of the plant Galega officinalis, also called goat's rue, long before modern pharmacology described how it worked. It has been a mainstay of type 2 diabetes treatment for decades and is on national and global essential medicines lists.

Its main action is on the liver. In type 2 diabetes the liver keeps releasing glucose even when blood levels are already high, and metformin dampens that output. It also improves how sensitive muscle and fat tissue are to insulin, so the insulin a person still makes is used more efficiently. It has a modest effect on glucose absorption from the gut as well.

Crucially, metformin does not stimulate the pancreas to release extra insulin. That is why it is not usually a strong cause of low blood sugar by itself, and why it is comfortable to build other medicines on top of it.

Sitagliptin belongs to a newer class known as DPP-4 inhibitors, sometimes called gliptins. Their target is a natural system called the incretin effect.

When food reaches the intestine, the gut releases hormones such as GLP-1 and GIP. These hormones tell the pancreas to release insulin in proportion to the meal and tell the alpha cells to release less glucagon, the hormone that pushes the liver to make glucose. The body then breaks these hormones down within minutes using an enzyme called dipeptidyl peptidase-4, or DPP-4.

Sitagliptin blocks that enzyme. The incretin signal therefore lasts longer and works harder at exactly the moment it is needed, after eating. Because the effect is glucose-dependent, it fades when blood sugar is not high, which is why gliptins are generally considered gentle on the risk of hypoglycaemia when used without a sulfonylurea or insulin.

Within the class, gliptins are broadly similar in how they act. They differ in dose, in how they are cleared from the body and in how they are handled in kidney impairment, which is one reason a doctor may prefer one over another.

Type 2 diabetes is progressive for most people. A medicine that worked well at diagnosis often needs support a few years later, and adding a second agent is usually more effective than pushing the first one higher.

Sitagliptin and metformin pair well because they attack different steps. Metformin reduces hepatic glucose production and improves insulin sensitivity between meals and overnight. Sitagliptin sharpens the after-meal insulin response and reduces glucagon. Neither one duplicates the other's job.

A fixed-dose combination such as Sitomni-M-OD 100/500 adds a practical advantage on top of the pharmacology. Fewer tablets and fewer timings mean a regimen that is easier to follow day after day, which matters a great deal in a condition treated for decades. A once-daily format takes that one step further for patients who struggle with mid-day doses.

The trade-off is flexibility. Once two molecules are fixed in one tablet, adjusting only one of them means changing to a different strength or going back to separate tablets. That is a decision for the prescriber, based on readings, tolerance and kidney function.

Oral treatment for type 2 diabetes in India spans several classes: biguanides, sulfonylureas such as glimepiride, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones and alpha-glucosidase inhibitors, alongside injectable options including insulin and GLP-1 receptor agonists.

Metformin is generally the starting point unless there is a reason to avoid it. What is added next depends on the individual: the size of the gap to target, kidney function, heart and kidney disease history, hypoglycaemia risk, weight considerations and affordability.

A gliptin and metformin combination is a common and well-understood next step, particularly where a low risk of hypoglycaemia and a simple once-daily regimen are priorities.

This article is for general information only and is not a substitute for advice from a registered medical practitioner.